CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $889,000, lower than 95% of all stocks globally
- PositionOperating margin is -19881.9%, lower than 95% of its Biotechnology peers (median -34.2%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
489.34MUSDvs all stocks (USD)
Revenue (TTM)
889.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.68xvs all stocks
52-Week Change
-49.69%vs all stocks
Market Capitalization
489.34MUSDvs all stocks (USD)
Enterprise Value
1.40BUSDvs all stocks (USD)
Forward P/E
-2.81xvs Biotechnology peers
Enterprise to Revenue
1.57Kxvs Biotechnology peers
Enterprise to EBITDA
-8.63xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-30.15%vs Biotechnology peers
Revenue (TTM)
889.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0060USDUpdated Jul 19, 2026Quarterly Revenue Growth
-1.70%vs Biotechnology peers
Gross Profit (TTM)
889.00KUSDvs all stocks (USD)
EBITDA (TTM)
-161.92MUSDvs all stocks (USD)
Net Income (TTM)
-72.29MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.74%vs Biotechnology peers
Operating Cash Flow (TTM)
-132.21MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-78.63MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
1.31BUSDFY2025 · Dec 31, 2025Revenue
893.00KUSDFY2025 · Dec 31, 2025Operating Income
-165.01MUSDvs all stocks (USD)
Pre-tax Income
-151.20MUSDFY2025 · Dec 31, 2025Income Tax Expense
414.00KUSDFY2025 · Dec 31, 2025Net Income
-151.61MUSDFY2025 · Dec 31, 2025EBIT
-151.19MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-144.62MUSDFY2025 · Dec 31, 2025Research & Development
114.12MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
51.78MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.81MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
4.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5200USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
133.94MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
133.94MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-151.61MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
82.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-124.33MUSDFY2025 · Dec 31, 2025Free Cash Flow
-139.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
108.54MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-151.61MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.58MUSDFY2025 · Dec 31, 2025Stock-based Compensation
25.34MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-29.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.32MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-5.92MUSDFY2025 · Dec 31, 2025Capital Expenditures
-15.20MUSDFY2025 · Dec 31, 2025Purchase of Investments
-217.08MUSDFY2025 · Dec 31, 2025Sale of Investments
318.02MUSDFY2025 · Dec 31, 2025Other Investing Activity
18.21MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
103.97MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-26.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
24.22MUSDFY2025 · Dec 31, 2025Shares Outstanding
141.98MSharesUpdated Jul 19, 2026Shares Short
19.43MSharesUpdated Jul 19, 2026Short Ratio
13.40daysvs all stocks
Short % of Shares Outstanding
12.81%vs all stocks
% Held by Insiders
47.30%vs all stocks
% Held by Institutions
24.40%vs all stocks
Total Cash (MRQ)
224.94MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.10USDUpdated Jul 19, 2026Total Debt (MRQ)
3.78MUSDvs all stocks (USD)
Current Ratio (MRQ)
9.06xvs Biotechnology peers
Book Value per Share (MRQ)
-7.21USDUpdated Jul 19, 2026Total Assets
335.57MUSDvs all stocks (USD)
Total Current Assets
280.68MUSDFY2025 · Dec 31, 2025Total Liabilities
34.78MUSDFY2025 · Dec 31, 2025Total Non-current Assets
54.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.04MUSDFY2025 · Dec 31, 2025Total Current Liabilities
30.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
108.54MUSDFY2025 · Dec 31, 2025Other Short-term Investments
161.48MUSDFY2025 · Dec 31, 2025Accounts Payable
940.00KUSDFY2025 · Dec 31, 2025Short-term Debt
1.07MUSDFY2025 · Dec 31, 2025Long-term Debt
2.96MUSDFY2025 · Dec 31, 2025Common Stock (Book)
30.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.27BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
300.79MUSDvs all stocks (USD)
52-Week Low
1.53USDUpdated Jul 19, 202652-Week High
3.55USDUpdated Jul 19, 202652-Week Change
-49.69%vs all stocks
Beta
1.68xvs all stocks
50-Day MA
1.77USDUpdated Jul 19, 2026200-Day MA
2.17USDUpdated Jul 19, 2026Avg 10-Day Volume
1.25MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.38MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.5300USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -19881.9%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -198.819Industry median: -0.34Industry P5: -43.55Peers compared: 261
Financial Health
Altman Z-Score 2.55: grey zoneSignificant
Altman Z-Score: 2.55
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $889,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 889,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Transtek Medical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
OrthoPediatrics Corp.
Tier 1ProductionApproval-Gated PipelineRule
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Succeeder Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hyundai Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ZJ Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Onconic Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule